Market open
Rigel Pharmaceuticals, Inc./$RIGL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Ticker
$RIGL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
163
ISIN
US7665597024
Website
RIGL Metrics
BasicAdvanced
$327M
8.77
$2.08
1.34
-
Price and volume
Market cap
$327M
Beta
1.34
52-week high
$25.42
52-week low
$15.50
Average daily volume
209K
Financial strength
Current ratio
2.2
Quick ratio
1.781
Long term debt to equity
461.981
Total debt to equity
544.229
Interest coverage (TTM)
5.56%
Management effectiveness
Return on assets (TTM)
18.15%
Return on equity (TTM)
-567.43%
Valuation
Price to earnings (TTM)
8.773
Price to revenue (TTM)
1.589
Price to book
17.59
Price to tangible book (TTM)
-41.11
Price to free cash flow (TTM)
9.132
Growth
Revenue change (TTM)
70.16%
Earnings per share change (TTM)
-283.53%
3-year revenue growth (CAGR)
37.89%
3-year earnings per share growth (CAGR)
-25.12%
RIGL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Rigel Pharmaceuticals, Inc. stock?
Rigel Pharmaceuticals, Inc. (RIGL) has a market cap of $327M as of May 15, 2025.
What is the P/E ratio for Rigel Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Rigel Pharmaceuticals, Inc. (RIGL) stock is 8.77 as of May 15, 2025.
Does Rigel Pharmaceuticals, Inc. stock pay dividends?
No, Rigel Pharmaceuticals, Inc. (RIGL) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Rigel Pharmaceuticals, Inc. dividend payment date?
Rigel Pharmaceuticals, Inc. (RIGL) stock does not pay dividends to its shareholders.
What is the beta indicator for Rigel Pharmaceuticals, Inc.?
Rigel Pharmaceuticals, Inc. (RIGL) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.